Francis Cuss is a physician-scientist, with a background in general and academic medicine, who has developed a broad experience in pharmaceutical research, in clinical development and in executive management within globally-operating biopharma companies during a career of more than 30 years in the pharmaceutical industry; specifically with Bristol-Myers Squibb, Schering-Plough and Glaxo.
Francis retired from Bristol-Myers Squibb in July 2017 having served as Executive Vice President, Chief Scientific Officer and head of R&D since July 2013 and as a member of BMS’s Senior Management Team since 2010. He joined Bristol-Myers Squibb in 2003, and as head of Research for nearly a decade Francis led a very productive discovery organization which produced a pipeline of innovative medicines from both in-house and external programs; helping numerous patients prevail against serious disease and laying the foundation for significant company growth.
He is a member of the board of directors of Novo Holdings A/S, Denmark and Rubius Therapeutics, and Vice Chair of the Board of Trustees of Montclair State University, NJ.
Prior to joining the pharmaceutical industry, Francis was a practicing physician with a specialization in pulmonary medicine in the UK. He received his education and medical training in the United Kingdom.
He holds medical degrees from Cambridge University, U.K. and is a fellow of the Royal College of Physicians and the Faculty of Pharmaceutical Medicine. He has published numerous articles and book chapters on topics of medical interest and organizational effectiveness.